Abstrakt

Przypisy

• 1. Abboud S., Karhunen P.J., Lütjohann D., Goebeler S., Luoto T.,Friedrichs S., Lehtimaki T., Pandolfo M., Laaksonen R.: Proproteinconvertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor oflarge-vessel atherosclerosis stroke. PLoS One, 2007; 2: e1043
  Google Scholar
• 2. Adkison K.K., Vaidya S.S., Lee D.Y., Koo S.H., Li L., Mehta A.A.,Gross A.S., Polli J.W., Lou Y., Lee E.J.: The ABCG2 C421A polymorphismdoes not affect oral nitrofurantoin pharmacokinetics inhealthy Chinese male subjects. Br. J. Clin. Pharmacol., 2008; 66:233-239
  Google Scholar
• 3. Akadam-Teker B., Kurnaz O., Coskunpinar E., Daglar-AdayA., Kucukhuseyin O., Cakmak H.A., Teker E., Bugra Z., OzturkO., Yilmaz-Aydogan H.: The effects of age and gender on therelationship between HMGCR promoter-911 SNP (rs33761740)and serum lipids in patients with coronary heart disease. Gene,2013; 528: 93-98
  Google Scholar
• 4. Akao H., Polisecki E., Kajinami K., Trompet S., Robertson M., FordI., Jukema J.W., de Craen A.J., Westendorp R.G., Shepherd J., PackardC., Buckley B.M., Schaefer E.J.: KIF6, LPA, TAS2R50, and VAMP8 geneticvariation, low density lipoprotein cholesterol lowering responseto pravastatin, and heart disease risk reduction in the elderly. Atherosclerosis,2012; 220: 456-462
  Google Scholar
• 5. Awan Z., Seidah N.G., MacFadyen J.G., Benjannet S., Chasman D.I.,Ridker P.M., Genest J.: Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: theJUPITER trial. Clin. Chem., 2012; 58: 183-189
  Google Scholar
• 6. Bellosta S., Paoletti R., Corsini A.: Safety of statins: focus on clinicalpharmacokinetics and drug interactions. Circulation, 2004; 109:III-50-III-57
  Google Scholar
• 7. Benn M., Nordestgaard B.G., Grande P., Schnohr P., Tybjaerg-Hansen A.: PCSK9 R46L, low-density lipoprotein cholesterol levels,and risk of ischemic heart disease: 3 independent studies and metaanalyses.J. Am. Coll. Cardiol., 2010; 55: 2833-2842
  Google Scholar
• 8. Bhatt D.L., Paré G., Eikelboom J.W., Simonsen K.L., Emison E.S.,Fox K.A., Steg P.G., Montalescot G., Bhakta N., Hacke W., FlatherM.D., Mak K.H., Cacoub P., Creager M.A., Berger P.B., Steinhubl S.R.,Murugesan G., Mehta S.R., Kottke-Marchant K., Lincoff A.M., TopolE.J., CHARISMA Investigators: The relationship between CYP2C19polymorphisms and ischaemic and bleeding outcomes in stableoutpatients: the CHARISMA genetics study. Eur. Heart J., 2012; 33:2143-2150
  Google Scholar
• 9. Chasman D.I., Giulianini F., MacFadyen J., Barratt B.J., Nyberg F.,Ridker P.M.: Genetic determinants of statin-induced low-densitylipoprotein cholesterol reduction: the Justification for the Use ofStatins in Prevention: an Intervention Trial Evaluating Rosuvastatin(JUPITER) trial. Circ. Cardiovasc. Genet., 2012; 5: 257-264
  Google Scholar
• 10. Chen S.N., Ballantyne C.M., Gotto A.M.Jr, Tan Y., Willerson J.T.,Marian A.J.: A common PCSK9 haplotype, encompassing the E670Gcoding single nucleotide polymorphism, is a novel genetic markerfor plasma low-density lipoprotein cholesterol levels and severityof coronary atherosclerosis. J. Am. Coll. Cardiol., 2005; 45: 1611-1619
  Google Scholar
• 11. Chen Y.C., Chen Y.D., Li X., Post W., Herrington D., Polak J.F.,Rotter J.I., Taylor K.D.: The HMG-CoA reductase gene and lipid andlipoprotein levels: the multi-ethnic study of atherosclerosis. Lipids,2009; 44: 733-743
  Google Scholar
• 12. Chien K.L., Wang K.C., Chen Y.C., Chao C.L., Hsu H.C., Chen M.F.,Chen W.J.: Common sequence variants in pharmacodynamic andpharmacokinetic pathway-related genes conferring LDL cholesterolresponse to statins. Pharmacogenomics, 2010; 11: 309-317
  Google Scholar
• 13. Chu A.Y., Guilianini F., Grallert H., Dupuis J., Ballantyne C.M.,Barratt B.J., Nyberg F., Chasman D.I., Ridker P.M.: Genome-wide associationstudy evaluating lipoprotein-associated phospholipase A2mass and activity at baseline and after rosuvastatin therapy. Circ.Cardiovasc. Genet., 2012; 5: 676-685
  Google Scholar
• 14. Chung J.Y., Cho S.K., Oh E.S., Lee D.H., Lim L.A., Jang S.B., Lee Y.J.,Park K., Park M.S.: Effect of HMGCR variant alleles on low-densitylipoprotein cholesterol-lowering response to atorvastatin in healthyKorean subjects. J. Clin. Pharmacol., 2012; 52: 339-346
  Google Scholar
• 15. Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H.: Sequencevariations in PCSK9, low LDL, and protection against coronary heartdisease. N. Engl. J. Med., 2006; 354: 1264-1272
  Google Scholar
• 16. Danik J.S., Chasman D.I., MacFadyen J.G., Nyberg F., Barratt B.J.,Ridker P.M.: Lack of association between SLCO1B1 polymorphismsand clinical myalgia following rosuvastatin therapy. Am. Heart J.,2013; 165: 1008-1014
  Google Scholar
• 17. de Keyser C.E., Peters B.J., Becker M.L., Visser L.E., UitterlindenA.G., Klungel O.H., Verstuyft C., Hofman A., Maitland-van der ZeeA.H., Stricker B.H.: The SLCO1B1 c.521T>C polymorphism is associatedwith dose decrease or switching during statin therapy in theRotterdam Study. Pharmacogenet. Genomics, 2014; 24: 43-51
  Google Scholar
• 18. DeGorter M.K., Tirona R.G., Schwarz U.I., Choi Y.H., Dresser G.K.,Suskin N., Myers K., Zou G., Iwuchukwu O., Wei W.Q., Wilke R.A.,Hegele R.A., Kim R.B.: Clinical and pharmacogenetic predictors ofcirculating atorvastatin and rosuvastatin concentrations in routineclinical care. Circ. Cardiovasc. Genet., 2013; 6: 400-408
  Google Scholar
• 19. Delgado P., Chacón P., Penalba A., Pelegri D., García-BerrocosoT., Giralt D., Santamarina E., Ribó M., Maisterra O., Alvarez-Sabín J.,Rosell A., Montaner J.: Lipoprotein-associated phospholipase A(2)activity is associated with large-artery atherosclerotic etiology andrecurrent stroke in TIA patients. Cerebrovasc. Dis., 2012; 33: 150-158
  Google Scholar
• 20. Delgado P., Chacón P., Penalba A., Pelegrí D., Merino C., RibóM., Rubiera M., Álvarez-Sabin J., Montaner J.: Temporal profile andprognostic value of Lp-PLA2 mass and activity in the acute strokesetting. Atherosclerosis, 2012; 220: 532-536
  Google Scholar
• 21. Deng S., Zhu G., Liu F., Zhang H., Qin X., Li L., Zhiyi H.: CYP4F2gene V433M polymorphism is associated with ischemic stroke in themale Northern Chinese Han population. Prog. Neuropsychopharmacol.Biol. Psychiatry, 2010; 34: 664-648
  Google Scholar
• 22. Deshmukh H.A., Colhoun H.M., Johnson T., McKeigue P.M., BetteridgeD.J., Durrington P.N., Fuller J.H., Livingstone S., Charlton-Menys V., Neil A., Poulter N., Sever P., Shields D.C., Stanton A.V.,Chatterjee A., et al.: Genome-wide association study of genetic determinantsof LDL-c response to atorvastatin therapy: importanceof Lp(a). J. Lipid Res., 2012; 53: 1000-1011
  Google Scholar
• 23. Ding H., Cui G., Zhang L., Xu Y., Bao X., Tu Y., Wu B., Wang Q.,Hui R., Wang W., Dackor R.T., Kissling G.E., Zeldin D.C., Wang D.W.:Association of common variants of CYP4A11 and CYP4F2 with strokein the Han Chinese population. Pharmacogenet. Genomics, 2010;20: 187-194
  Google Scholar
• 24. Donnelly L.A., Doney A.S., Dannfald J., Whitley A.L., Lang C.C.,Morris A.D., Donnan P.T., Palmer C.N.: A paucimorphic variant in theHMG-CoA reductase gene is associated with lipid-lowering responseto statin treatment in diabetes: a GoDARTS study. Pharmacogenet.Genomics, 2008; 18: 1021-1026
  Google Scholar
• 25. Donnelly L.A., van Zuydam N.R., Zhou K., Tavendale R., Carr F.,Maitland-van der Zee A.H., Leusink M., de Boer A., Doevendans P.A.,Asselbergs F.W., Morris A.D., Pearson E.R., Klungel O.H., Doney A.S.,Palmer C.N.: Robust association of the LPA locus with low-densitylipoprotein cholesterol lowering response to statin treatment ina meta-analysis of 30 467 individuals from both randomized controltrials and observational studies and association with coronaryartery disease outcome during statin treatment. Pharmacogenet.Genomics, 2013; 23: 518-525
  Google Scholar
• 26. Enquobahrie D.A., Smith N.L., Bis J.C., Carty C.L., Rice K.M., LumleyT., Hindorff L.A., Lemaitre R.N., Williams M.A., Siscovick D.S.,Heckbert S.R., Psaty B.M.: Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, andToll-like receptor 4 genetic variations and risk of incident nonfatalmyocardial infarction and ischemic stroke. Am. J. Cardiol., 2008;101: 1683-1688
  Google Scholar
• 27. Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., ThompsonA., White I.R., Marcovina S.M., Collins R., Thompson S.G., Danesh J.:Lipoprotein(a) concentration and the risk of coronary heart disease,stroke, and nonvascular mortality. JAMA, 2009; 302: 412-423
  Google Scholar
• 28. Fava C., Montagnana M., Almgren P., Rosberg L., Lippi G., HedbladB., Engström G., Berglund G., Minuz P., Melander O.: The V433M variantof the CYP4F2 is associated with ischemic stroke in male Swedesbeyond its effect on blood pressure. Hypertension, 2008; 52: 373-380
  Google Scholar
• 29. Fidani L., Hatzitolios A.I., Goulas A., Savopoulos C., BasayannisC., Kotsis A.: Cholesteryl ester transfer protein TaqI B and lipoproteinlipase Ser447Ter gene polymorphisms are not associated withischaemic stroke in Greek patients. Neurosci. Lett., 2005; 384: 102-105
  Google Scholar
• 30. Freitas R.N., Khaw K.T., Wu K., Bowman R., Jeffery H., Luben R.,Wareham N.J., Rodwell S.: HMGCR gene polymorphism is associatedwith stroke risk in the EPIC-Norfolk study. Eur. J. Cardiovasc. Prev.Rehabil., 2010; 17: 89-93
  Google Scholar
• 31. Fu Q., Li Y.P., Gao Y., Yang S.H., Lu P.Q., Jia M., Zhang L.R.: Lack ofassociation between SLCO1B1 polymorphism and the lipid-loweringeffects of atorvastatin and simvastatin in Chinese individuals. Eur.J. Clin. Pharmacol., 2013; 69: 1269-1274 32 Funk M., Freitag R., Endler G., Lalouschek W., Lang W., MannhalterC., Sunder-Plassmann R.: Influence of cytochrome P450 2C92and 2C93 variants on the risk of ischemic stroke: a cross-sectionalcase-control study. Clin. Chem., 2005; 51: 1716-1718
  Google Scholar
• 32. prospective studies. Lancet, 2010; 375: 1536-1544
  Google Scholar
• 33. Gao J., Cong H.L., Mao Y.M., Liu Y., Zhang N., Chen Q., Liu T., CuiR.: Influence of CETP gene -629C/A polymorphism on the efficacyof atorvastatin treatment and clinical outcome. Zhonghua Yi XueYi Chuan Xue Za Zhi, 2013; 30: 553-558
  Google Scholar
• 34. Gao Y., Zhang L.R., Fu Q.: CYP3A41G polymorphism is associatedwith lipid-lowering efficacy of atorvastatin but not of simvastatin.Eur. J. Clin. Pharm., 2008; 64: 877-882
  Google Scholar
• 35. Genvigir F.D., Soares S.A., Hirata M.H., Willrich M.A., Arazi S.S.,Rebecchi I.M., Oliveira R., Bernik M.M., Dorea E.L., Bertolami M.C.,Hirata R.D.: Effects of ABCA1 SNPs, including the C-105T novel variant,on serum lipids of Brazilian individuals. Clin. Chim. Acta, 2008;389: 79-86
  Google Scholar
• 36. Hamrefors V., Orho-Melander M., Krauss R.M., Hedblad B.,Almgren P., Berglund G., Melander O.: A gene score of nine LDL andHDL regulating genes is associated with fluvastatin-induced cholesterolchanges in women. J. Lipid Res., 2010; 51: 625-634
  Google Scholar
• 37. Helgadottir A., Gretarsdottir S., Thorleifsson G., Holm H., PatelR.S., Gudnason T., Jones G.T., van Rij A.M., Eapen D.J., Baas A.F.,Tregouet D.A., Morange P.E., Emmerich J., Lindblad B., Gottsäter A.et al.: Apolipoprotein(a) genetic sequence variants associated withsystemic atherosclerosis and coronary atherosclerotic burden butnot with venous thromboembolism. J. Am. Coll. Cardiol., 2012; 60:722-729
  Google Scholar
• 38. Hindorff L.A., Lemaitre R.N., Smith N.L., Bis J.C., Marciante K.D.,Rice K.M., Lumley T., Enquobahrie D.A., Li G., Heckbert S.R., PsatyB.M.: Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarctionand stroke. Pharmacogenet. Genomics, 2008; 18: 677-682
  Google Scholar
• 39. Hopewell J.C., Clarke R., Parish S., Armitage J., Lathrop M.,Hager J., Collins R., Heart Protection Study Collaborative Group:Lipoprotein(a) genetic variants associated with coronary and peripheralvascular disease but not with stroke risk in the Heart ProtectionStudy. Circ. Cardiovasc. Genet., 2011; 4: 68-73
  Google Scholar
• 40. Hopewell J.C., Parish S., Offer A., Link E., Clarke R., Lathrop M.,Armitage J., Collins R.: MRC/BHF Heart Protection Study CollaborativeGroup. Impact of common genetic variation on response to simvastatintherapy among 18 705 participants in the Heart ProtectionStudy. Eur. Heart J., 2013; 34: 982-992
  Google Scholar
• 41. Horejsi B., Spacil J., Ceska R., Vrablík M., Haas T., Horínek A.: Theindependent correlation of the impact of lipoprotein(a) levels andapolipoprotein E polymorphism on carotid artery intima thickness.Int. Angiol., 2000; 19: 331-336
  Google Scholar
• 42. Hsu L.A., Teng M.S., Ko Y.L., Chang C.J., Wu S., Wang C.L., HuC.F.: The PCSK9 gene E670G polymorphism affects low-density lipoproteincholesterol levels but is not a risk factor for coronaryartery disease in ethnic Chinese in Taiwan. Clin. Chem. Lab. Med.,2009; 47: 154-158
  Google Scholar
• 43. Hu M., Mak V.W., Tomlinson B.: Polymorphisms in apolipoproteinE and apolipoprotein A-V do not influence the lipid responseto rosuvastatin but are associated with baseline lipid levels in Chinesepatients with hyperlipidemia. J. Clin. Lipidol., 2012; 6: 585-592
  Google Scholar
• 44. Huang Y., Ballinger D.G., Stokowski R., Beilharz E., Robinson J.G.,Liu S., Robinson R.D., Henderson V.W., Rossouw J.E., Prentice R.L.: Exploringthe interaction between SNP genotype and postmenopausalhormone therapy effects on stroke risk. Genome Med., 2012; 4: 57
  Google Scholar
• 45. Hubacek J.A., Dlouha D., Adámkova V., Lanska V., Ceska R., VrablikM.: Possible gene-gender interaction between the SLCO1B1 polymorphismand statin treatment efficacy. Neur. Endocrinol. Lett., 2012; 33,Suppl. 2: 22-25
  Google Scholar
• 46. Jia D.M., Chen Z.B., Zhang M.J., Yang W.J., Jin J.L., Xia Y.Q., ZhangC.L., Shao Y., Chen C., Xu Y.: CYP2C19 polymorphisms and antiplateleteffects of clopidogrel in acute ischemic stroke in China. Stroke,2013; 44: 1717-1719
  Google Scholar
• 47. Kaur-Knudsen D., Bojesen S.E., Nordestgaard B.G.: Commonpolymorphisms in CYP2C9, subclinical atherosclerosis and risk ofischemic vascular disease in 52,000 individuals. PharmacogenomicsJ., 2009; 9: 327-332
  Google Scholar
• 48. Keskitalo J.E., Pasanen M.K., Neuvonen P.J., Niemi M.: Differenteffects of the ABCG2 c.421C>A SNP on the pharmacokinetics offluvastatin, pravastatin and simvastatin. Pharmacogenomics, 2009;10: 1617-1624
  Google Scholar
• 49. Keskitalo J.E., Zolk O., Fromm M.F., Kurkinen K.J., NeuvonenP.J., Niemi M.: ABCG2 polymorphism markedly affects the pharmacokineticsof atorvastatin and rosuvastatin. Clin. Pharmacol. Ther..2009; 86: 197-203
  Google Scholar
• 50. Kirchheiner J., Kudlicz D., Meisel C., Bauer S., Meineke I., Roots I.,Brockmöller J.: Influence of CYP2C9 polymorphisms on the pharmacokineticsand cholesterol-lowering activity of (-)-3S,5R-fluvastatinand (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol.Ther., 2003;74: 186-194
  Google Scholar
• 51. Kotake H., Sekikawa A., Tokita Y., Ishigaki Y., Oikawa S.: Effectof HMG-CoA reductase inhibitor on plasma cholesteryl ester transferprotein activity in primary hypercholesterolemia: comparisonamong CETP/TaqIB genotype subgroups. J. Atheroscler. Thromb.,2002; 9: 207-212
  Google Scholar
• 52. Kotlęga D., Ciećwież S., Turowska-Kowalska J., Nowacki P.: Pathogeneticjustification of statin use in ischaemic stroke prevention accordingto inflammatory theory in development of atherosclerosis.Neurol. Neurochir. Pol,. 2012; 46: 176-183
  Google Scholar
• 53. Kotlęga D., Nowacki P., Białecka M., Kurzawski M., Droździk M.,Ciećwież S.: Association between CRP gene polymorphism 717A/G,C-reactive protein and neurological deficit in ischemic stroke. J. Clin.Neurosci., 2014; 21: 574-577
  Google Scholar
• 54. Lee J.D., Lee T.H., Kuo Y.W., Huang Y.C., Hsu H.L., Lin Y.H., WuC.Y., Huang Y.C., Lee M., Hsiao K.M.: Polymorphisms at the LDLRlocus may be associated with ischemic cerebrovascular disease independentof lipid profile. Curr. Neurovasc. Res., 2012; 9: 200-206
  Google Scholar
• 55. Li Z.G., Li G., Zhou Y.L., Chen Z.J., Yang J.Q., Zhang Y., Sun S.,Zhong S.L.: Lack of association between lipoprotein(a) genetic variantsand subsequent cardiovascular events in Chinese Han patientswith coronary artery disease after percutaneous coronary intervention.Lipids Health Dis., 2013; 12: 127
  Google Scholar
• 56. Link E., Parish S., Armitage J., Bowman L., Heath S., Matsuda F.,Gut I., Lathrop M., Collins R., SEARCH Collaborative Group: SLCO1B1variants and statin-induced myopathy – a genomewide study. N.Engl. J. Med., 2008; 359: 789-799
  Google Scholar
• 57. Lu Y., Tayebi N., Li H., Saha N., Yang H., Heng C.K.: Associationof CETP Taq1B and -629C > A polymorphisms with coronary arterydisease and lipid levels in the multi-ethnic Singaporean population.Lipids Health Dis., 2013; 12: 85
  Google Scholar
• 58. Luke M.M., O‘Meara E.S., Rowland C.M., Shiffman D., Bare L.A.,Arellano A.R., Longstreth W.T. Jr, Lumley T., Rice K., Tracy R.P., DevlinJ.J., Psaty B.M.: Gene variants associated with ischemic stroke: thecardiovascular health study. Stroke, 2009; 40: 363-368
  Google Scholar
• 59. Maggo S.D., Kennedy M.A., Clark D.W.: Clinical implicationsof pharmacogenetic variation on the effects of statins. Drug Saf.,2011; 34: 1-19
  Google Scholar
• 60. Maitland-van der Zee A.H., Stricker B.H., Klungel O.H., KasteleinJ.J., Hofman A., Witteman J.C., Breteler M.M., Leufkens H.G., van DuijnC.M., de Boer A.: The effectiveness of hydroxy-methylglutaryl coenzymeA reductase inhibitors (statins) in the elderly is not influencedby apolipoprotein E genotype. Pharmacogenetics, 2002; 12: 647-653
  Google Scholar
• 61. Malaguarnera M., Vacante M., Russo C., Malaguarnera G., AnticT., Malaguarnera L., Bella R., Pennisi G., Galvano F., Frigiola A.:Lipoprotein(a) in cardiovascular diseases. Biomed. Res. Int., 2013;2013: 650989
  Google Scholar
• 62. Mangravite L.M., Medina M.W., Cui J., Pressman S., Smith J.D.,Rieder M.J., Guo X., Nickerson D.A., Rotter J.I., Krauss R.M.: Combinedinfluence of LDLR and HMGCR sequence variation on lipidloweringresponse to simvastatin. Arterioscler. Thromb. Vasc. Biol.,2010; 30: 1485-1492
  Google Scholar
• 63. Marciante K.D., Totah R.A., Heckbert S.R., Smith N.L., LemaitreR.N., Lumley T., Rice K.M., Hindorff L.A., Bis J.C., Hartman B., PsatyB.M.: Common variation in cytochrome P450 epoxygenase genesand the risk of incident nonfatal myocardial infarction and ischemicstroke. Pharmacogenet. Genomics, 2008; 18: 535-543
  Google Scholar
• 64. Massot A., Pelegri D., Penalba A., Arenillas J., Boada C., Giralt D.,Ribó M., Molina C.A., Rosell A., Alvarez-Sabín J., Chacón P., Rovira A.,Delgado P., Montaner J.: Lipoprotein-associated phospholipase A2testing usefulness among patients with symptomatic intracranialatherosclerotic disease. Atherosclerosis, 2011; 218: 181-187
  Google Scholar
• 65. Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., SimonT., Antman E.M., Braunwald E., Sabatine M.S.: Genetic variants inABCB1 and CYP2C19 and cardiovascular outcomes after treatmentwith clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogeneticanalysis. Lancet, 2010; 376: 1312-1319
  Google Scholar
• 66. Muallem H., North K.E., Kakoki M., Wojczynski M.K., Li X., GroveM., Boerwinkle E., Wilhelmsen K.C., Heiss G., Maeda N.: Quantitativeeffects of common genetic variations in the 3‘UTR of the humanLDL-receptor gene and their associations with plasma lipid levelsin the Atherosclerosis Risk in Communities study. Hum. Genet.,2007; 121: 421-431
  Google Scholar
• 67. Mulder A.B., van Lijf H.J., Bon M.A., van den Bergh F.A., Touw D.J.,Neef C., Vermes I.: Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatinAssociationof polymorphism in the cytochrome CYP2D6 and the efficacy andtolerability of simvastatin. Clin. Pharmacol. Ther., 2001; 70: 546-551
  Google Scholar
• 68. Munshi A., Sharma V., Kaul S., Al-Hazzani A., Alshatwi A.A., ShafiG., Koppula R., Mallemoggala S.B., Jyothy A.: Association of 1347G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertensionand stroke. Mol. Biol. Rep., 2012; 39: 1677-1682
  Google Scholar
• 69. Musialek P., Tracz W., Tekieli L., Pieniazek P., Kablak-ZiembickaA., Przewlocki T., Stepien E., Kapusta P., Motyl R., Stepniewski J., UndasA., Podolec P.: Multimarker approach in discriminating patientswith symptomatic and asymptomatic atherosclerotic carotid arterystenosis. J. Clin. Neurol., 2013; 9: 165-175
  Google Scholar
• 70. O’Donoghue M., Morrow D.A., Sabatine M.S., Murphy S.A., Mc-Cabe C.H., Cannon C.P., Braunwald E.: Lipoprotein-associated phospholipaseA2 and its association with cardiovascular outcomes inpatients with acute coronary syndromes in the PROVE IT-TIMI 22(PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation, 2006; 113:1745-1752.
  Google Scholar
• 71. Papp A.C., Pinsonneault J.K., Wang D., Newman L.C., Gong Y.,Johnson J.A., Pepine C.J., Kumari M., Hingorani A.D., Talmud P.J.,Shah S., Humphries S.E., Sadee W.: Cholesteryl ester transfer protein(CETP) polymorphisms affect mRNA splicing, HDL levels, and sexdependentcardiovascular risk. PLoS One, 2012; 7: e31930
  Google Scholar
• 72. Peters B.J., Pett H., Klungel O.H., Stricker B.H., Psaty B.M., GlazerN.L., Wiggins K.L., Bis J.C., de Boer A, Maitland-van der Zee A.H.: Geneticvariability within the cholesterol lowering pathway and theeffectiveness of statins in reducing the risk of MI. Atherosclerosis,2011; 217: 458-464
  Google Scholar
• 73. Polisecki E., Muallem H., Maeda N., Peter I., Robertson M., Mc-Mahon A.D., Ford I., Packard C., Shepherd J., Jukema J.W., WestendorpR.G., de Craen A.J., Buckley B.M., Ordovas J.M., Schaefer E.J., etal.: Genetic variation at the LDL receptor and HMG-CoA reductasegene loci, lipid levels, statin response, and cardiovascular diseaseincidence in PROSPER. Atherosclerosis, 2008; 200: 109-114
  Google Scholar
• 74. Polisecki E., Peter I., Robertson M., McMahon A.D., Ford I., PackardC., Shepherd J., Jukema J.W., Blauw G.J., Westendorp R.G., deCraen A.J., Trompet S., Buckley B.M., Murphy M.B., Ordovas J.M.,Schaefer E.J., PROSPER Study Group: Genetic variation at the PCSK9locus moderately lowers low-density lipoprotein cholesterol levels,but does not significantly lower vascular disease risk in an elderlypopulation. Atherosclerosis, 2008; 200: 95-101
  Google Scholar
• 75. Prueksaritanont T., Ma B., Yu N.: The human hepatic metabolismof simvastatin hydroxy acid is mediated primarily by CYP3A, andnot CYP2D6. Br. J. Clin. Pharmacol., 2003; 56: 120-124
  Google Scholar
• 76. Qi Q., Workalemahu T., Zhang C., Hu F.B., Qi L.: Genetic variants,plasma lipoprotein(a) levels, and risk of cardiovascular morbidityand mortality among two prospective cohorts of type 2 diabetes.Eur. Heart J., 2012; 33: 325-334
  Google Scholar
• 77. Quarta G., Stanzione R., Evangelista A., Zanda B., Sciarretta S.,Di Angelantonio E., Marchitti S., Di Murro D., Volpe M., Rubattu S.:A protective role of a cholesteryl ester transfer protein gene varianttowards ischaemic stroke in Sardinians. J. Intern. Med., 2007;262: 555-561
  Google Scholar
• 78. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M.,Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., Macfadyen J.G.,Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. JUPITERTrial Study Group: Reduction in C-reactive protein and LDL cholesteroland cardiovascular event rates after initiation of rosuvastatin:a prospective study of the JUPITER trial. Lancet, 2009; 373: 1175-1182
  Google Scholar
• 79. Rodrigues A.C., Sobrino B., Genvigir F.D., Willrich M.A., AraziS.S., Dorea E.L., Bernik M.M., Bertolami M., Faludi A.A., Brion M.J.,Carracedo A., Hirata M.H., Hirata R.D.: Genetic variants in genesrelated to lipid metabolism and atherosclerosis, dyslipidemia andatorvastatin response. Clin. Chim. Acta, 2013; 417: 8-11
  Google Scholar
• 80. Ronald J., Rajagopalan R., Cerrato F., Nord A.S., Hatsukami T.,Kohler T., Marcovina S., Heagerty P., Jarvik G.P.: Genetic variation inLPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotidartery disease risk. Stroke, 2011; 42: 2-9
  Google Scholar
• 81. Sandholzer C., Saha N., Kark J.D., Rees A., Jaross W., Dieplinger H.,Hoppichler F., Boerwinkle E., Utermann G.: Apo(a) isoforms predictrisk for coronary heart disease: a study in six populations. Arterioscl.Thrombosis, 1992; 12: 1214-1226
  Google Scholar
• 82. Scartezini M., Hubbart C., Whittall R.A., Cooper J.A., Neil A.H.,Humphries S.E.: The PCSK9 gene R46L variant is associated withlower plasma lipid levels and cardiovascular risk in healthy U.K.men. Clin. Sci., 2007; 113: 435-441
  Google Scholar
• 83. Shabana M.F., Mishriki A.A., Issac M.S., Bakhoum S.W.: Do MDR1and SLCO1B1 polymorphisms influence the therapeutic response toatorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.Mol. Diagn. Ther., 2013; 17: 299-309
  Google Scholar
• 84. Shiffman D., Slawsky K., Fusfeld L., Devlin J.J., Goss T.F.: Costeffectivenessmodel of use of genetic testing as an aid in assessingthe likely benefit of aspirin therapy for primary prevention of cardiovasculardisease. Clin. Ther., 2012; 34: 1387-1394
  Google Scholar
• 85. Song Y., Stampfer M.J., Liu S.: Meta-analysis: apolipoprotein Egenotypes and risk for coronary heart disease. Ann. Intern. Med.,2004; 141: 137-147
  Google Scholar
• 86. Sudlow C., Martínez González N.A., Kim J., Clark C.: Does apolipoproteinE genotype influence the risk of ischemic stroke, intracerebralhemorrhage, or subarachnoid hemorrhage? Systematicreview and meta-analyses of 31 studies among 5961 cases and 17,965controls. Stroke, 2006; 37: 364-370
  Google Scholar
• 87. Szaefer H., Cichocki M., Majchrzak-Celińska A.: New cytochromeP450 isoforms as cancer biomarkers and targets for chemopreventiveand chemotherapeutic agents. Postępy Hig. Med. Dośw., 2013;67: 709-718
  Google Scholar
• 88. Ten Kate G.J., Neefjes L.A., Dedic A., Nieman K., Langendonk J.G.,Galema-Boers A.J., Roeters van Lennep J., Moelker A., Krestin G.P.,Sijbrands E.J., de Feyter P.J.: The effect of LDLR-negative genotype onCT coronary atherosclerosis in asymptomatic statin treated patientswith heterozygous familial hypercholesterolemia. Atherosclerosis,2013; 227: 334-341
  Google Scholar
• 89. Terry J.G., Howard G., Mercuri M., Bond M.G., Crouse J.R.3rd.:Apolipoprotein E polymorphism is associated with segment-specificextracranial carotid artery intima-media thickening. Stroke, 1996;27: 1755-1759
  Google Scholar
• 90. The National Center for Biotechnology Information. ABCA1 ATPbindingcassette, sub-family A (ABC1), member 1 [Homo sapiens (human)]. 2013 http://www.ncbi.nlm.nih.gov/gene/19. Accessed onlineDecember 28, 2013
  Google Scholar
• 91. The National Center for Biotechnology Information. CETP cholesterylester transfer protein, plasma [Homo sapiens (human)]. 2014.http://www.ncbi.nlm.nih.gov/gene/1071. Accessed online January18, 2014
  Google Scholar
• 92. The National Center for Biotechnology Information. CYP2C8cytochrome p450, family 2, subfamily C, polypeptide 8 [Homo sapiens(human)]. 2014. http://www.ncbi.nlm.nih.gov/gene/1558. Accessedonline January 12, 2014
  Google Scholar
• 93. The National Center for Biotechnology Information. SLCO1B1solute carrier organic anion transporter family, member 1B1 [Homosapiens (human)]. 2013. http://www.ncbi.nlm.nih.gov/gene/10599.Accessed online December 13, 2013
  Google Scholar
• 94. Thompson A., Gao P., Orfei L., Watson S., Di Angelantonio E., KaptogeS., Ballantyne C., Cannon C.P., Criqui M., Cushman M., HofmanA., Packard C., Thompson S.G., Collins R., Danesh J., Lp-PLA(2) StudiesCollaboration: Lipoprotein-associated phospholipase A(2) and riskof coronary disease, stroke, and mortality: collaborative analysis of
  Google Scholar
• 95. Thompson J.F., Hyde C.L., Wood L.S., Paciga S.A., Hinds D.A., CoxD.R., Hovingh G.K., Kastelein J.J.: Comprehensive whole-genome andcandidate gene analysis for response to statin therapy in the Treatingto New Targets (TNT) cohort. Circ. Cardiovasc. Genet., 2009; 2:173-181
  Google Scholar
• 96. Tomlinson B., Hu M., Lee V.W., Lui S.S., Chu T.T., Poon E.W., KoG.T., Baum L., Tam L.S., Li E.K.: ABCG2 polymorphism is associatedwith the low-density lipoprotein cholesterol response to rosuvastatin.Clin. Pharmacol. Ther., 2010; 87: 558-562
  Google Scholar
• 97. Tsai T.H., Chen Y.L., Lin H.S., Liu C.F., Chang H.W., Lu C.H., ChangW.N., Chen S.F., Wu C.J., Leu S., Ko S.F., Yip H.K.: Link between lipoprotein-associated phospholipase A2 gene expression of peripheralbloodmononuclear cells and prognostic outcome after acute ischemicstroke. J. Atheroscler. Thromb., 2012; 19: 523-531
  Google Scholar
• 98. Tu Y., Cui G., Xu Y., Bao X., Wang X., Wang D.W.: Genetic polymorphismof CYP11B2 gene and stroke in the Han Chinese populationand a meta-analysis. Pharmacogenet. Genomics, 2011; 21: 115-120
  Google Scholar
• 99. Vieira J.R., Whittall R.A., Cooper J.A., Miller G.J., Humphries S.E.:The A370T variant (StuI polymorphism) in the LDL receptor gene isnot associated with plasma lipid levels or cardiovascular risk in UKmen. Ann. Hum. Genet., 2006; 70: 697-704
  Google Scholar
• 100. Virani S.S., Lee V.V., Brautbar A., Grove M.L., Nambi V., AlamM., Elayda M., Wilson J.M., Willerson J.T., Boerwinkle E., BallantyneC.M.: Single nucleotide polymorphisms in cholesteryl ester transferprotein gene and recurrent coronary heart disease or mortalityin patients with established atherosclerosis. Am. J. Cardiol., 2013;112: 1287-1292
  Google Scholar
• 101. Volcik K.A., Barkley R.A., Hutchinson R.G., Mosley T.H., HeissG., Sharrett A.R., Ballantyne C.M., Boerwinkle E.: Apolipoprotein Epolymorphisms predict low density lipoprotein cholesterol levelsand carotid artery wall thickness but not incident coronary heartdisease in 12,491 ARIC study participants. Am. J. Epidemiol,. 2006;164: 342-348
  Google Scholar
• 102. Voora D., Shah S.H., Reed C.R., Zhai J., Crosslin D.R., Messer C.,Salisbury B.A., Ginsburg G.S.: Pharmacogenetic predictors of statinmediatedlow-density lipoprotein cholesterol reduction and doseresponse. Circ. Cardiovasc. Genet., 2008; 1: 100-106
  Google Scholar
• 103. Voora D., Shah S.H., Spasojevic I., Ali S., Reed C.R., SalisburyB.A., Ginsburg G.S.: The SLCO1B15 genetic variant is associated withstatin-induced side effects. J. Am. Coll. Cardiol., 2009; 54: 1609-1616
  Google Scholar
• 104. Vrablík M., Hubáček J.A., Dlouhá D., Lánská V., Rynekrová J., Zlatohlávek L., Prusíková M., Ceška R., Adámková V.: Impact of variantswithin seven candidate genes on statin treatment efficacy. Physiol.Res., 2012; 61: 609-617
  Google Scholar
• 105. Wang Q.Y., Wang W.J., Wu L., Liu L., Han L.Z.: Meta-analysisof APOE ε2/ε3/ε4 polymorphism and cerebral infarction. J. Neural.Transm., 2013; 120: 1479-1489
  Google Scholar
• 106. Whirl-Carrillo M., McDonagh E.M., Hebert J.M., Gong L.,Sangkuhl K., Thorn C.F., Altman R.B., Klein T.E.: PharmacogenomicsKnowledge for Personalized Medicine. Clin. Pharmacol. Ther.,2012; 92: 414-417
  Google Scholar
• 107. White H.: Editorial: why inhibition of lipoprotein-associatedphospholipase A2 has the potential to improve patient outcomes.Curr. Opin. Cardiol., 2010; 25: 299-301
  Google Scholar
• 108. Willrich M.A., Hirata M.H., Genvigir F.D., Arazi S.S., RebecchiI.M., Rodrigues A.C., Bernik M.M., Dorea E.L., Bertolami M.C., FaludiA.A., Hirata R.D.: CYP3A5–3A allele is associated with reducedlowering-lipid response to atorvastatin in individuals with hypercholesterolemia.Clin. Chim. Acta, 2008; 398: 15-20
  Google Scholar
• 109. Yin Y.W., Sun Q.Q., Zhang B.B., Hu A.M., Liu H.L., Wang Q., HouZ.Z.: Association between apolipoprotein E gene polymorphism andthe risk of coronary artery disease in Chinese population: evidencefrom a meta-analysis of 40 studies. PLoS One, 2013; 8: e66924
  Google Scholar
• 110. Zanger U.M., Turpeinen M., Klein K., Schwab M.: Functionalpharmacogenetics/genomics of human cytochromes P450 involvedin drug biotransformation. Anal. Bioanal. Chem., 2008; 392: 1093-1108
  Google Scholar
• 111. Zende P.D., Bankar M.P., Kamble P.S., Momin A.A.: Apolipoproteine gene polymorphism and its effect on plasma lipids in arteriosclerosis.J. Clin. Diagn. Res., 2013; 7: 2149-2152
  Google Scholar
• 112. Zhang W., Yu B.N., He Y.J., Fan L., Li Q., Liu Z.Q., Wang A., Liu Y.L.,Tan Z.R., Fen-Jiang, Huang Y.F., Zhou H.H.: Role of BCRP 421C>A polymorphismon rosuvastatin pharmacokinetics in healthy Chinesemales. Clin. Chim. Acta, 2006; 373: 99-103
  Google Scholar
• 113. Zhou Q., Ruan Z.R., Yuan H., Xu D.H., Zeng S.: ABCB1 gene polymorphisms,ABCB1 haplotypes and ABCG2 c.421c > A are determinantsof inter-subject variability in rosuvastatin pharmacokinetics.Pharmazie, 2013; 68: 129-134
  Google Scholar

Pełna treść artykułu